Lasa Supergenerics

Lasa Supergenerics EBIT per Employee

The EBIT per Employee of Lasa Supergenerics (LASA.NS) as of Nov 3, 2026 is -3.85 M INR. In the previous year, EBIT per Employee was -677,955.06 INR — a change of 467.16% (lower).

EBIT per Employee

-3.85 MINR

YoY

467.16%

Last updated:

EBIT per Employee of Lasa Supergenerics is 2026 -3.85 M INR. EBIT per Employee of Lasa Supergenerics was 2025 -677,955.06 INR. It decreases by 467.16% lower compared to the previous year.

The Lasa Supergenerics EBIT per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Employee
Date
EBIT per Employee
Jan 1, 2019
-880,910.11 INR
Jan 1, 2020
1.42 M INR
Jan 1, 2021
3.53 M INR
Jan 1, 2022
261,235.96 INR
Jan 1, 2023
-4.28 M INR
Jan 1, 2024
-947,348.31 INR
Jan 1, 2025
-677,955.06 INR
Jan 1, 2026
-3.85 M INR
The Lasa Supergenerics EBIT per Employee history
YEAREBIT per EmployeeYoY
-3.85 MINR+467.16%
-677,955.06INR-28.44%
-947,348.31INR-77.87%
-4.28 MINR-1,738.90%
261,235.96INR-92.61%
3.53 MINR+148.97%
1.42 MINR-261.08%
-880,910.11INR-133.91%
2.60 MINR-39.31%
4.28 MINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lasa Supergenerics Stock analysis

What does Lasa Supergenerics do? Lasa Supergenerics Ltd manufactures veterinary preparations including API products such as Albendazole, Fenbendazole, Oxfendazole, Providone Iodine, Nitroxylene, Ricobendazole, Halquinol, and others. The company also produces animal feed ingredients like potassium iodide, cobalt sulfate, sodium selenate, ethylediamine dihydroiodide, and vanadyl sulfate, as well as reagents for therapeutic use including cetylpyridinium chloride, bismuth subsalicylate, and sodium selenite. Its manufacturing facility in Mahad and Chiplun, Maharashtra, supports the production of these specialized veterinary and pharmaceutical products. The company's primary customers are likely veterinary pharmaceutical manufacturers and animal health suppliers who require API products, feed additives, and therapeutic reagents. These segments include the veterinary pharmaceutical industry and animal feed production sectors, which rely on Lasa Supergenerics' specialized chemical formulations for their own product lines. The firm's focus on catalyst chemistry and anthelmintic/veterinary API products positions it within the niche market of veterinary pharmaceutical manufacturing. Lasa Supergenerics generates revenue through the sale of its API products, animal feed ingredients, and therapeutic reagents to veterinary and pharmaceutical companies. The company's product portfolio targets the veterinary pharmaceutical sector, where demand for anthelmintic and other API-based solutions is significant. By specializing in catalyst chemistry and producing high-demand veterinary API products, the company serves a specific market segment with tailored chemical solutions. Lasa Supergenerics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lasa Supergenerics stock

EBIT per Employee of Lasa Supergenerics is -3.85 M INR in 2026.

EBIT per Employee of Lasa Supergenerics changed from -677,955.06 INR to -3.85 M INR, representing a 467.16% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Employee Lasa Supergenerics since 2006 – with annual values, charts, and detailed analysis.

EBIT per employee measures operating profit per employee, showing how efficiently the workforce generates operating earnings.

EBIT per Employee's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT per Employee's Lasa Supergenerics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Lasa Supergenerics

All Key Metrics — Lasa Supergenerics